The SINCERE Intervention to Address COVID-19 Health Disparities
Part of paid clinical trials in Salt Lake City, Utah.
- Sponsor
- Andrea Wallace
- Study ID
- NCT05228886
- Status
- Recruiting
Conditions
- COVID-19
- Social Determinants of Health
- Vulnerable Populations
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- SINCERE — BEHAVIORALEach goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered "action plan" specifying what, when, how much, and how often patients will engage in a behavior (e.g., "I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening"). Again, following clear prompts, ISs negotiate the "action plan" with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10.
- Scheduled Follow-Up — BEHAVIORALAdding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
- Standard of Care — OTHER211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
Study Details
The goal of this real world efficacy study is to understand the benefit of universal social needs screening, community-based service referrals, and telephonic follow-up as a scalable strategy for preventing COVID-19 transmission, and for addressing the secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic. With statewide community service providers, existing health information technology, and piloted methods, we seek to determine the effectiveness of universal social needs screening and community service referrals - the SINCERE intervention - in improving health outcomes of COVID-19 vulnerable and socioeconomically disadvantaged populations and whether intensive follow-up and collaborative goal-setting helps overcome barriers to community service use by patients seen in the emergency department and seeking COVID testing at community-based and mobile clinic locations.
Key Dates
- Start date
- Sep 27, 2021
- Status verified
- Sep 2025
- Primary completion
- Mar 31, 2025
- Completion
- Mar 31, 2026
Study Design
- Enrollment
- 1,500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Active Comparator: Call + ResourcesParticipants receive standard care typically provided to 211 callers, including ad hoc follow-up.
- Experimental: Call + Resources + Scheduled Follow-UpParticipants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the Scheduled Follow-Up intervention description.
- Experimental: Call + Resources + SINCEREParticipants receive standard care typically provided to 211 callers plus scheduled follow-up calls according to the SINCERE intervention description (scheduled follow up with active collaborative goal setting).
Primary Outcome Measure
Change in Global Health over 12-week time period [ Time Frame: Baseline, 2-week, 4-week and 12-week surveys ]
Central Contacts
- Ernest Grigorian801-707-2775
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Utah | Salt Lake City | Utah | 84112 |
Find similar trials in Salt Lake City, UT
Related Studies
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseasePHASE3 · Recruiting · Pfizer · Phoenix, Arizona
- Viral Infections in Healthy and Immunocompromised HostsRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyPHASE3 · Recruiting · Ansun Biopharma, Inc. · Duarte, California
- Positron Emission Tomography (PET) Imaging of ThrombosisPHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts